21:27:54 EDT Thu 08 May 2025
Enter Symbol
or Name
USA
CA



Sirona Biochem Corp
Symbol SBM
Shares Issued 263,643,145
Close 2025-01-15 C$ 0.055
Market Cap C$ 14,500,373
Recent Sedar Documents

Sirona Biochem sees Stonegate report highlight TFC-1326

2025-01-15 18:39 ET - News Release

Mr. Christopher Hopton reports

SIRONA BIOCHEM SHOWCASES TFC-1326 IN STONEGATE HEALTHCARE'S LANDMARK REPORT

Sirona Biochem Corp.'s cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners' latest research report. The publication, titled "Sirona Biochem's TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326's clinical trial performance, setting it apart from traditional retinoid treatments.

The report outlines the remarkable benefits of TFC-1326, including:

  • Boosting skin radiance;
  • Significantly reducing wrinkle depth and volume;
  • Enhancing skin elasticity and firmness;
  • Ensuring deep hydration with no irritation.

Stonegate Healthcare's analysis underscores TFC-1326's ability to deliver rapid, consistent results while also providing potent anti-oxidant and anti-inflammatory benefits. Unlike traditional retinoids, which can cause irritation, TFC-1326 is ideal for all skin types, including sensitive skin, redefining what is possible in the $12.5-billion global anti-aging market.

"This recognition by Stonegate Healthcare Partners highlights the transformative potential of TFC-1326," said Dr. Verrico, chief executive officer of Sirona Biochem. "Our mission has always been to push the boundaries of skin care science, and we are proud to see our innovation recognized in this detailed analysis."

The publication positions TFC-1326 as a disruptive force in cosmetic dermatology, offering a highly effective, user-friendly alternative to conventional treatments. This achievement reflects Sirona Biochem's continuing commitment to pioneering advanced solutions in the skin care industry.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona Biochem specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona Biochem's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments. Sirona Biochem's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.